Harmony Biosciences
HRMY
216 hedge funds and large institutions have $1.68B invested in Harmony Biosciences in 2023 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 83 increasing their positions, 78 reducing their positions, and 52 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 78
0.41% more ownership
Funds ownership: 85.67% → 86.07% (+0.41%)
10% less funds holding
Funds holding: 240 → 216 (-24)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
38% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 52
40% less capital invested
Capital invested by funds: $2.78B → $1.68B (-$1.1B)
52% less call options, than puts
Call options by funds: $4.05M | Put options by funds: $8.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$58.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$21.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$13.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$56.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$32.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$29.4M |
| 4 |
PA
Perceptive Advisors
New York
|
-$14.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.1M |
HRMY Hedge Fund Activity: Q1 2023 in Review
216 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2023, worth a combined $1.68B — down 40% from $2.78B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of HRMY and 32 opened new positions — a net loss of 20 holders — while 78 trimmed existing stakes and 83 added.
The largest buyer was Adage Capital Partners, adding an estimated $58.5M. The largest seller was Janus Henderson Group, cutting an estimated $56.5M.
- 216 institutional investors held Harmony Biosciences (HRMY) as of Q1 2023, down from 240 in Q4 2022.
- Funds reported $1.68B of Harmony Biosciences stock for Q1 2023, down 40% quarter-over-quarter.
- 32 funds opened new Harmony Biosciences positions in Q1 2023 and 52 closed out, a net change of -20 holders.
- The largest Harmony Biosciences buyer in Q1 2023 was Adage Capital Partners, an estimated $58.5M added.
- The largest Harmony Biosciences seller in Q1 2023 was Janus Henderson Group, an estimated $56.5M sold.
Based on aggregated 13F filings for Q1 2023.